These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12230485)

  • 1. Future of icodextrin as an osmotic agent in peritoneal dialysis.
    Pecoits-Filho R; Mujais S; Lindholm B
    Kidney Int Suppl; 2002 Oct; (81):S80-7. PubMed ID: 12230485
    [No Abstract]   [Full Text] [Related]  

  • 2. Biocompatibility of icodextrin.
    Cooker LA; Holmes CJ; Hoff CM
    Kidney Int Suppl; 2002 Oct; (81):S34-45. PubMed ID: 12230480
    [No Abstract]   [Full Text] [Related]  

  • 3. Peritoneal transport characteristics with glucose polymer-based dialysis fluid in children.
    Rusthoven E; Krediet RT; Willems HL; Monnens LA; Schröder CH
    J Am Soc Nephrol; 2004 Nov; 15(11):2940-7. PubMed ID: 15504948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on peritoneal dialysis solutions.
    García-López E; Lindholm B; Davies S
    Nat Rev Nephrol; 2012 Feb; 8(4):224-33. PubMed ID: 22349485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritoneal transport with icodextrin solution.
    Heimbürger O
    Contrib Nephrol; 2006; 150():97-103. PubMed ID: 16720998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Icodextrin: a review of its use in peritoneal dialysis.
    Frampton JE; Plosker GL
    Drugs; 2003; 63(19):2079-105. PubMed ID: 12962523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Icodextrin as first treatment: reasons to be optimistic].
    Rivera M
    Nefrologia; 2009; 29(2):99-102. PubMed ID: 19396313
    [No Abstract]   [Full Text] [Related]  

  • 8. Kinetic analysis of peritoneal fluid and solute transport with combination of glucose and icodextrin as osmotic agents.
    Galach M; Werynski A; Waniewski J; Freida P; Lindholm B
    Perit Dial Int; 2009; 29(1):72-80. PubMed ID: 19164256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical considerations when prescribing icodextrin: a narrative review.
    Silver SA; Harel Z; Perl J
    Am J Nephrol; 2014; 39(6):515-27. PubMed ID: 24925229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of clinical trial experience with icodextrin.
    Wolfson M; Ogrinc F; Mujais S
    Kidney Int Suppl; 2002 Oct; (81):S46-52. PubMed ID: 12230481
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel "bimodal" use of icodextrin peritoneal dialysis solutions.
    Burkart J
    Kidney Int; 1998 Apr; 53(4):1089-90. PubMed ID: 9551423
    [No Abstract]   [Full Text] [Related]  

  • 12. Icodextrin: an alternative peritoneal dialysis fluid.
    Chhabra D; Nash K
    Expert Opin Drug Metab Toxicol; 2008 Nov; 4(11):1455-64. PubMed ID: 18950286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal transport after long-term exposure to Icodextrin in rats.
    Frajewicki V; Kushnir D; Wajsbrot V; Kohan R; Shostak A; Gotloib L
    Nephron; 2002 Sep; 92(1):174-82. PubMed ID: 12187100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Icodextrin in peritoneal dialysis therapy].
    Grzegorzewska AE; Antczak-Jedrzejczak D
    Przegl Lek; 1999; 56(12):812-6. PubMed ID: 10789195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of osmotic and oncotic factors on gentamicin and insulin transport across the peritoneal membrane in vitro.
    Grzelak T; Wojciechowska K; Szary B; Czyzewska K
    Adv Perit Dial; 2011; 27():16-21. PubMed ID: 22073822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Crystalloid versus Colloid Osmosis across the Peritoneal Membrane.
    Morelle J; Sow A; Fustin CA; Fillée C; Garcia-Lopez E; Lindholm B; Goffin E; Vandemaele F; Rippe B; Öberg CM; Devuyst O
    J Am Soc Nephrol; 2018 Jul; 29(7):1875-1886. PubMed ID: 29844208
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of using icodextrin as a starting therapy for peritoneal permeability].
    Fernández-Reyes MJ; Bajo MA; del Peso G; Olea T; Sánchez-Villanueva RL; González E; Heras M; Sánchez R; Selgas R
    Nefrologia; 2009; 29(2):130-5. PubMed ID: 19396318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutritional effects of increasing dialysis dose by adding an icodextrin daytime dwell to Nocturnal Intermittent Peritoneal Dialysis (NIPD) in children.
    van Hoeck KJ; Rusthoven E; Vermeylen L; Vandesompel A; Marescau B; Lilien M; Schroder CH
    Nephrol Dial Transplant; 2003 Jul; 18(7):1383-7. PubMed ID: 12808177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early quality of life benefits of icodextrin in peritoneal dialysis.
    Guo A; Wolfson M; Holt R
    Kidney Int Suppl; 2002 Oct; (81):S72-9. PubMed ID: 12230484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Biocompatibility of Neutral Icodextrin Peritoneal Dialysis Fluid.
    Shimada S; Mori T; Koizumi K; Sato S; Oba-Yabana I; Ohsaki Y; Sato E; Naganuma E; Kurasawa N; Tsuchikawa M; Ito S
    Adv Perit Dial; 2016; 32():46-50. PubMed ID: 28988589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.